Patents Assigned to Sankyo Company Limited
  • Publication number: 20220016257
    Abstract: An object of the present invention is to provide an antibody specifically binding to CDH6 and having a high internalization activity, an antibody-drug conjugate comprising the antibody and a high antitumor activity, a pharmaceutical product having the antibody-drug conjugate and having a therapeutic effect on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. According to the present invention, it is possible to provide an anti-CDH6 antibody prepared having internalization activity, an anti-CDH6 antibody-drug conjugate prepared by connecting the anti-CDH6 antibody and a novel PBD derivative and exhibiting high anti-tumor activity, a pharmaceutical product and a therapeutic method for treating tumors using these.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 20, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Naoya HARADA, Kozo YONEDA, Ichiro HAYAKAWA, Masaki MEGURO, Fuminao DOI
  • Publication number: 20220008549
    Abstract: Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.
    Type: Application
    Filed: September 6, 2019
    Publication date: January 13, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Toshifumi TSUDA, Toshiki TABUCHI, Hideaki WATANABE, Hiroyuki KOBAYASHI, Masayuki ISHIZAKI, Kyoko HARA, Teiji WADA, Masami ARAI
  • Publication number: 20220010026
    Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.
    Type: Application
    Filed: June 28, 2021
    Publication date: January 13, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuki SATOH, Kazuki HIRAHARA, Ichiro WATANABE, Masato AMANO
  • Publication number: 20220002385
    Abstract: A method for improving blood kinetics of a peptide is provided. The method for improving blood kinetics of a peptide includes a step of preparing a peptide having a modified amino acid sequence.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 6, 2022
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Hidenori Yano
  • Patent number: 11208403
    Abstract: The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 28, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Noriyasu Haginoya, Takashi Suzuki, Miho Hayakawa, Masahiro Ota, Tomoharu Tsukada, Katsuhiro Kobayashi, Yosuke Ando, Takeshi Jimbo, Koichi Nakamura
  • Patent number: 11208467
    Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: December 28, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • Patent number: 11208442
    Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase that is isolated from a fungus belonging to the genus Rhizomucor and is active under high-temperature conditions; various mutant enzymes thereof; genes encoding the enzymes; a recombinant plasmid; a transformant transformed with the plasmid; and the like.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 28, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hanako Ito, Yasunori Ono, Kensuke Nakamura
  • Publication number: 20210393601
    Abstract: An object of the present invention is to provide a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect. Provided is a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect.
    Type: Application
    Filed: November 29, 2019
    Publication date: December 23, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Daisuke HONMA
  • Publication number: 20210386865
    Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeru NOGUCHI, Ken SAKURAI, Daisuke OKAJIMA
  • Patent number: 11185594
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 30, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
  • Publication number: 20210355087
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2019
    Publication date: November 18, 2021
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
  • Patent number: 11173213
    Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 16, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeru Noguchi, Ken Sakurai, Daisuke Okajima
  • Publication number: 20210347836
    Abstract: To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.
    Type: Application
    Filed: June 21, 2019
    Publication date: November 11, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Tatsuya Inoue
  • Publication number: 20210340221
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 4, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • Publication number: 20210340628
    Abstract: A method for identifying a subject suffering from a cancer, comprising: obtaining a biological sample from the human patient diagnosed as suffering from a cancer; evaluating an amount of expression of the hTROP2 gene at mRNA level in the biological sample; evaluating an amount of expression of the SLFN11 gene at mRNA level in the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the hTROP2 gene; and identifying the human patient who provided the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the SLFN11 gene, as a subject to whom a medicament containing an anti-hTROP2 antibody is to be given.
    Type: Application
    Filed: August 22, 2019
    Publication date: November 4, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke OKAJIMA, Satoru YASUDA, Kei ENOMOTO
  • Publication number: 20210332149
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Patent number: 11149066
    Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 19, 2021
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, PEPTIDREAM INC.
    Inventors: Takahiro Yamaguchi, Yutaka Mori, Hironao Saito, Hideki Kubota, Akihiro Furukawa, Eri Otsuka, Yutaka Ishigai, Hiroshi Ijiri, Patrick Reid
  • Publication number: 20210317498
    Abstract: The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transfected cells having a novel Hspa8 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transfected cells.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 14, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Masuda, Yuto Nakazawa, Kazuhiko Watanabe, Maui Nishio, Takeshi Okumura, Koichi Nonaka
  • Publication number: 20210290775
    Abstract: A pharmaceutical composition, wherein an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond, and a tubulin inhibitor are administered in combination, and a method of treatment, wherein the antibody-drug conjugate and the tubulin inhibitor are administered in combination to a subject.
    Type: Application
    Filed: August 5, 2019
    Publication date: September 23, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yusuke OGITANI, Chiaki ISHII, Yasuki KAMAI, Kiyoshi SUGIHARA, Shotaro NAGASE
  • Publication number: 20210290777
    Abstract: A therapeutic agent for a metastatic brain tumor comprising, as an active component, an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond and/or a method of treatment for a metastatic brain tumor, comprising administering the antibody-drug conjugate to a subject in need of the treatment for a metastatic brain tumor.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 23, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kiyoshi SUGIHARA, Chiaki ISHII